(Z)-methyl 2-[(dimethylamino)methylene]-3-oxoheptanoate | 1019258-87-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: (Z)-methyl 2-[(dimethylamino)methylene]-3-oxoheptanoate
• 英文别名: (z)-Methyl 2-((dimethylamino)methylene)-3-oxoheptanoate；methyl (2Z)-2-(dimethylaminomethylidene)-3-oxoheptanoate
• CAS: 1019258-87-7
• 化学式: C₁₁H₁₉NO₃
• 分子量: 213.277
• InChiKey: KSLJRECIPISBTB-HJWRWDBZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (Z)-methyl 2-[(dimethylamino)methylene]-3-oxoheptanoate 在 水 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 溶剂黄146 、 N,N-二异丙基乙胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 二氯甲烷 为溶剂， 反应 20.0h， 生成 5-butyl-N-[(1,2-dimethyl-1H-imidazol-5-yl)methyl]-1-[5-methyl-4-(2-thienyl)pyrimidin-2-yl]-1H-pyrazole-4-carboxamide
  参考文献：
  名称：

  Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes

  摘要：

  GPR142 is a G protein-coupled receptor that is predominantly expressed in pancreatic beta-cells. GPR142 agonists stimulate insulin secretion in the presence of high glucose concentration, so that they could be novel insulin secretagogues with reduced or no risk of hypoglycemia. We report here the optimization of HTS hit compound 1 toward a proof of concept compound 33, which showed potent glucose lowering effects during an oral glucose tolerance test in mice and monkeys.

  DOI：

  10.1021/ml400186z
• 作为产物：
  描述：

  3-酮庚酸甲酯 、 N,N-二甲基甲酰胺二甲基缩醛 反应 24.0h， 生成 (Z)-methyl 2-[(dimethylamino)methylene]-3-oxoheptanoate
  参考文献：
  名称：

  Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes

  摘要：

  GPR142 is a G protein-coupled receptor that is predominantly expressed in pancreatic beta-cells. GPR142 agonists stimulate insulin secretion in the presence of high glucose concentration, so that they could be novel insulin secretagogues with reduced or no risk of hypoglycemia. We report here the optimization of HTS hit compound 1 toward a proof of concept compound 33, which showed potent glucose lowering effects during an oral glucose tolerance test in mice and monkeys.

  DOI：

  10.1021/ml400186z

文献信息

• SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281
  申请人：GILL Adrian Liam

  公开号：US20090264401A1

  公开（公告）日：2009-10-22

  A compound of formula (I): and pharmaceutically-acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described.

  一种具有化学式（I）的化合物： 及其药用盐，其中变量基团在其中定义；还描述了它们在抑制11βHSD1中的应用，制备它们的方法以及包含它们的药物组合物。
• N-aryl pyrazole compounds, compositions, and methods for their use
  申请人：Ogawa Yasuyuki

  公开号：US20080153778A1

  公开（公告）日：2008-06-26

  Compounds having formula I: where A 1 , A 2 , L, V, W, R 1 , R 2 , R 3 , R 4 and R 5 are as described herein, compositions thereof, and their use for the treatment or prevention of type 2 diabetes and type 2 diabetes-related conditions are provided herein.

  本文提供化学式为I的化合物，其中A1、A2、L、V、W、R1、R2、R3、R4和R5如本文所述，以及其组合物，并用于治疗或预防2型糖尿病和2型糖尿病相关疾病。
• WO2008/45484
  申请人：——

  公开号：——

  公开（公告）日：——
• N-ARYL PYRAZOLE COMPOUNDS FOR USE AGAINST DIABETES
  申请人：Amgen Inc.

  公开号：EP2079728A1

  公开（公告）日：2009-07-22
• US8022061B2
  申请人：——

  公开号：US8022061B2

  公开（公告）日：2011-09-20